Adding the programmed cell death protein-1 (PD-1) checkpoint inhibitor dostarlimab (Jemperli, GSK) to carboplatin and paclitaxel improves survival in patients with primary advanced or recurrent endometrial cancer, according to interim results from a phase 3 study.
Patients with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) tumors experienced the greatest benefit, with a 72% lower risk for disease progression during the median 25-month follow-up period, compared